Larotrectinib

(Vitrakvi)

Larotrectinib

Drug updated on 11/15/2023

Dosage FormCapsule (oral; 25 mg, 100 mg),Oral Solution (oral; 20 mg/mL)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation.
  • For the treatment of adult and pediatric patients with solid tumors that are metastatic or where surgical resection is likely to result in severe morbidity.
  • For the treatment of adult and pediatric patients with solid tumors that have no satisfactory alternative treatments or that have progressed following treatment.

Product Monograph / Prescribing Information

Document TitleYearSource
Vitrakvi (larotrectinib) Prescribing Information.2023Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Metastatic pancreatic cancer: ASCO guideline update.2020Journal of Clinical Oncology